Fentanyl inhalation - Aradigm Corporation

Drug Profile

Fentanyl inhalation - Aradigm Corporation

Latest Information Update: 20 Nov 2006

Price : $50

At a glance

  • Originator Aradigm Corporation
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer pain; Pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Jul 2002 Phase-I clinical trials in Cancer pain in Australia (Inhalation)
  • 30 Jul 2002 Phase-I clinical trials in Pain in Australia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top